Health Condition 1: I501- Left ventricular failure, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Novartis Healthcare Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Patients >= 18 years with a diagnosis of HFrEF as mentioned in database or heart failure with a recording of LVEF A prescription of sacubitril/valsartan
Exclusion criteria
Exclusion criteria: Diagnosis of HF specified as preserved/mid-range ejection fraction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following will be collated from EMRs to describe patient demographic and clinical characteristics at index date:Gender ,Age, Geographic area(divided into 4 zones- North, South, East and West),Functional Class (NYHA classification) HF etiology, Ventricular function defined by LVEF,Medical History,Laboratory parameters,Hospitalizations due to cardiovascular and non-cardiovascular causes, Concomitant medications classified as- Medications for HF & Medications for non-HF conditionsTimepoint: Index Date | — |
Secondary
| Measure | Time frame |
|---|---|
| Dose titration of sacubitril/valsartan: Assessed for a period of 6 months post index date. Key outcomes will be- Median value of maximum individual dose reached along with other descriptive statistics will be reported. Median time to first dose up-titration along with other descriptive statistics will be reported. Median time to target dose along with other descriptive statistics will be reported Timepoint: 6 months post index date;Persistence to sacubitril/valsartan: Defined as to time duration from initiation to discontinuation of therapy. Persistence up to 12 months post index date will be assessed using Kaplanâ??Meier (KM) methods. Multivariate Cox models will be used to explore potential factors that could contribute to time to discontinuation of therapy. Proportion of patient discontinuing sacubitril/valsartan at 2, 4, 6, 8 and 12 months will be monitored will be reported as frequency (n) and percentage (%). Timepoint: Initiation to Discontinuation of therapy | — |
Countries
India
Contacts
Public ContactDr Shankar Kumar
Novartis Healthcare Private Limited
Outcome results
None listed